Market Cap 32.10M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -8.12
Volume 722,200
Avg Vol 625,916
Day's Range N/A - N/A
Shares Out 40.00M
Stochastic %K 4%
Beta 2.79
Analysts Strong Sell
Price Target $7.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
WhereistheSEC
WhereistheSEC Jul. 29 at 6:00 AM
$ITRM The SHORT AND DISTORT action on this board has become HEAVY! Troy isn’t even bothering anymore…SEC DO YOUR F’ING JOB! Identify holders of short positions, track their IP and correlate to ST credentials, and F’N PROSECUTE!
1 · Reply
AceOfStonks
AceOfStonks Jul. 29 at 2:42 AM
$ITRM Launch date confirmed! 21 days to go. The virtual launch meeting for $ITRM Orlynvah™ marks the operational start of commercialization.
0 · Reply
Amb8675309
Amb8675309 Jul. 29 at 2:26 AM
$ITRM @Twillls08 totally agree- it’s a penem drug. Everything rests on the payors- medical community knows already what an important drug this is. Fishman is focused on a targeted launch: north east, Texas and Florida. It don’t be a full launch- more money is needed for that broader launch. Fishman is focused on revenue- that drive higher offers… the drug is fantastic, agree with you on current pricing as being an opportunity
0 · Reply
Twills08
Twills08 Jul. 29 at 2:09 AM
$ITRM 3) The recent drop in share price does not reek of dilution. In fact, ITRM is not so desperate as to do so at these levels. They have cash on hand. This appears to be retail shorts attacking at a time of quiet. This won’t last long, and the old adage “buy or hold” rings true here. The CTB remains quite low, and there are plenty of shares available. My best guess for a basement is 0.70, but this is obviously a guess. We are at 52 week lows. I am happy to accumulate more. 4) Buyout or commercialization: the $1 billion dollar question. I would put their buyout price right around there. A lot of you have expressed serious concerns about the recent 80mill share increase/dilution up for vote in September. I am similarly not happy, but when we ponder its timing, statements of “lowball” offers, and Eversana partnership, it’s reasonable to say that the C-suite is using their bag of tricks. They want to make it abundantly clear that BP can buy them and make $$ or they can go it alone.
0 · Reply
Twills08
Twills08 Jul. 29 at 2:01 AM
$ITRM Couple thoughts here as we dip lower during this period of quiet: 1) Orlynvah is a very different pharmaceutical product than Bluejepa. Orlynvah is a necessary cog in a wheel heretofore missing that piece. It is a very potent abx class with much needed oral coverage in a world of growing MDRO’s. Bluejepa is a new class of abx in general, which makes it novel; however, its application appears to be somewhat similar to its control (nitrofurantoin) in the phase trials. Bacteriocidal agents that act by preventing replication have their place, but they are not in line with a penem class abx. Not even close. It is like comparing a nuclear bomb to a .22 rifle round. $GSK deserves its rise, as a new novel class are relevant and exciting for future potential uses, but valuations for $ITRM will be much higher. 2) Orlynvah will have instant recognition in the medical community-> in applicable uses, duration of therapy, and spectrum of coverage. This is invaluable when marketing at large.
0 · Reply
D1onysus
D1onysus Jul. 29 at 1:31 AM
0 · Reply
look2theblue
look2theblue Jul. 29 at 1:19 AM
$ITRM $33M marketcap on an antibiotic with 15 years of patent life. Do we really think the first and only oral penem antibiotic really should be valued at $2.2m revenue per year? When you see a disconnect like this in valuation you jump on it.
1 · Reply
Keepitmoving
Keepitmoving Jul. 29 at 1:16 AM
$ITRM Don’t be hypnotized by handing Fishfuck more of your hard earned money in the form on dilution because he was ill prepared to launch and couldn’t accomplish a BO. I guess all the Durata analogies that these perma bulls on this board kept spewing actually isn’t materializing is it? Nothing these phony pumpers claim is materializing. I wish I didn’t know this playbook so well but it seems dilution is Fatman’s solution. And the next form of Fatman’s plan is a big fat reverse split. I’m calling it now for people like @WhereistheSEC that conveniently dismiss my correct predictions.
1 · Reply
donman150
donman150 Jul. 29 at 1:11 AM
$ITRM I look at the situation for how it is. Not more or less. ✅ CEO is known for acquisitions ✅ Orlynvah is FDA approved ready to launch ✅ Eversana Partnership for commercializing ✅ TAM is 26M looking for 1% penetration ✅ Script is $1,400 to $4,600 ✅ CEO actively looking for acquirers ✅ BOD all known for being successful ✅ Missing 8k for Christine Coyne ✅ Wild fluctuations in price - Shakeout ⛔Low on Cash ⛔Asking for 80M Authorized Shares ⛔Company silence is deafening ⛔No Institutional purchases ⛔Short interest went up by 650,000 I swear all of this pieces to the puzzle should make sense soon enough. Whether you have had years of waiting or months, the finish line is very close. I'm hoping for clarification on many things. The 80m authorized share raise, what is it for? An equity deal? How much 'skin in the game' does their partner have? What is the script going to be? What insurers will cover? Forward guidance basically.
1 · Reply
Amb8675309
Amb8675309 Jul. 29 at 12:49 AM
$ITRM on the BO situation: the lowball offers are there- as Fishman has said, “the door is always open”, the BOD wants a higher BO price- once we get revenue from Orlynvah scripts, now the market risk quantified and now BO talks can resume at the price we all want.
1 · Reply
Latest News on ITRM
Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript

May 13, 2025, 1:44 PM EDT - 2 months ago

Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript


Iterum Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025, 7:00 AM EDT - 2 months ago

Iterum Therapeutics Reports First Quarter 2025 Financial Results


Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript

Feb 7, 2025, 10:20 AM EST - 6 months ago

Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript


Iterum Therapeutics Regains Full Nasdaq Compliance

Nov 21, 2024, 8:30 AM EST - 8 months ago

Iterum Therapeutics Regains Full Nasdaq Compliance


Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 1:14 PM EST - 9 months ago

Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript


Iterum Therapeutics Reports Third Quarter 2024 Financial Results

Nov 14, 2024, 7:00 AM EST - 9 months ago

Iterum Therapeutics Reports Third Quarter 2024 Financial Results


US FDA approves Iterum's treatment for urinary infection

Oct 25, 2024, 10:57 AM EDT - 9 months ago

US FDA approves Iterum's treatment for urinary infection


Iterum Therapeutics to Present Data at IDWeek 2024

Oct 10, 2024, 8:30 AM EDT - 10 months ago

Iterum Therapeutics to Present Data at IDWeek 2024


Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript

Aug 16, 2024, 11:27 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript


Iterum Therapeutics Commences Rights Offering

Jul 22, 2024, 7:30 AM EDT - 1 year ago

Iterum Therapeutics Commences Rights Offering


Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 10:08 AM EDT - 1 year ago

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript


Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 10:32 AM EST - 1 year ago

Iterum Therapeutics plc (ITRM) Q3 2023 Earnings Call Transcript


Iterum Therapeutics to Present Data at IDWeek 2023

Oct 12, 2023, 9:15 AM EDT - 1 year ago

Iterum Therapeutics to Present Data at IDWeek 2023


Iterum Therapeutics plc (ITRM) Q2 2023 Earnings Call Transcript

Aug 11, 2023, 9:20 AM EDT - 2 years ago

Iterum Therapeutics plc (ITRM) Q2 2023 Earnings Call Transcript


Iterum Therapeutics to Present Data at ASM Microbe 2023

Jun 12, 2023, 6:23 PM EDT - 2 years ago

Iterum Therapeutics to Present Data at ASM Microbe 2023


WhereistheSEC
WhereistheSEC Jul. 29 at 6:00 AM
$ITRM The SHORT AND DISTORT action on this board has become HEAVY! Troy isn’t even bothering anymore…SEC DO YOUR F’ING JOB! Identify holders of short positions, track their IP and correlate to ST credentials, and F’N PROSECUTE!
1 · Reply
AceOfStonks
AceOfStonks Jul. 29 at 2:42 AM
$ITRM Launch date confirmed! 21 days to go. The virtual launch meeting for $ITRM Orlynvah™ marks the operational start of commercialization.
0 · Reply
Amb8675309
Amb8675309 Jul. 29 at 2:26 AM
$ITRM @Twillls08 totally agree- it’s a penem drug. Everything rests on the payors- medical community knows already what an important drug this is. Fishman is focused on a targeted launch: north east, Texas and Florida. It don’t be a full launch- more money is needed for that broader launch. Fishman is focused on revenue- that drive higher offers… the drug is fantastic, agree with you on current pricing as being an opportunity
0 · Reply
Twills08
Twills08 Jul. 29 at 2:09 AM
$ITRM 3) The recent drop in share price does not reek of dilution. In fact, ITRM is not so desperate as to do so at these levels. They have cash on hand. This appears to be retail shorts attacking at a time of quiet. This won’t last long, and the old adage “buy or hold” rings true here. The CTB remains quite low, and there are plenty of shares available. My best guess for a basement is 0.70, but this is obviously a guess. We are at 52 week lows. I am happy to accumulate more. 4) Buyout or commercialization: the $1 billion dollar question. I would put their buyout price right around there. A lot of you have expressed serious concerns about the recent 80mill share increase/dilution up for vote in September. I am similarly not happy, but when we ponder its timing, statements of “lowball” offers, and Eversana partnership, it’s reasonable to say that the C-suite is using their bag of tricks. They want to make it abundantly clear that BP can buy them and make $$ or they can go it alone.
0 · Reply
Twills08
Twills08 Jul. 29 at 2:01 AM
$ITRM Couple thoughts here as we dip lower during this period of quiet: 1) Orlynvah is a very different pharmaceutical product than Bluejepa. Orlynvah is a necessary cog in a wheel heretofore missing that piece. It is a very potent abx class with much needed oral coverage in a world of growing MDRO’s. Bluejepa is a new class of abx in general, which makes it novel; however, its application appears to be somewhat similar to its control (nitrofurantoin) in the phase trials. Bacteriocidal agents that act by preventing replication have their place, but they are not in line with a penem class abx. Not even close. It is like comparing a nuclear bomb to a .22 rifle round. $GSK deserves its rise, as a new novel class are relevant and exciting for future potential uses, but valuations for $ITRM will be much higher. 2) Orlynvah will have instant recognition in the medical community-> in applicable uses, duration of therapy, and spectrum of coverage. This is invaluable when marketing at large.
0 · Reply
D1onysus
D1onysus Jul. 29 at 1:31 AM
0 · Reply
look2theblue
look2theblue Jul. 29 at 1:19 AM
$ITRM $33M marketcap on an antibiotic with 15 years of patent life. Do we really think the first and only oral penem antibiotic really should be valued at $2.2m revenue per year? When you see a disconnect like this in valuation you jump on it.
1 · Reply
Keepitmoving
Keepitmoving Jul. 29 at 1:16 AM
$ITRM Don’t be hypnotized by handing Fishfuck more of your hard earned money in the form on dilution because he was ill prepared to launch and couldn’t accomplish a BO. I guess all the Durata analogies that these perma bulls on this board kept spewing actually isn’t materializing is it? Nothing these phony pumpers claim is materializing. I wish I didn’t know this playbook so well but it seems dilution is Fatman’s solution. And the next form of Fatman’s plan is a big fat reverse split. I’m calling it now for people like @WhereistheSEC that conveniently dismiss my correct predictions.
1 · Reply
donman150
donman150 Jul. 29 at 1:11 AM
$ITRM I look at the situation for how it is. Not more or less. ✅ CEO is known for acquisitions ✅ Orlynvah is FDA approved ready to launch ✅ Eversana Partnership for commercializing ✅ TAM is 26M looking for 1% penetration ✅ Script is $1,400 to $4,600 ✅ CEO actively looking for acquirers ✅ BOD all known for being successful ✅ Missing 8k for Christine Coyne ✅ Wild fluctuations in price - Shakeout ⛔Low on Cash ⛔Asking for 80M Authorized Shares ⛔Company silence is deafening ⛔No Institutional purchases ⛔Short interest went up by 650,000 I swear all of this pieces to the puzzle should make sense soon enough. Whether you have had years of waiting or months, the finish line is very close. I'm hoping for clarification on many things. The 80m authorized share raise, what is it for? An equity deal? How much 'skin in the game' does their partner have? What is the script going to be? What insurers will cover? Forward guidance basically.
1 · Reply
Amb8675309
Amb8675309 Jul. 29 at 12:49 AM
$ITRM on the BO situation: the lowball offers are there- as Fishman has said, “the door is always open”, the BOD wants a higher BO price- once we get revenue from Orlynvah scripts, now the market risk quantified and now BO talks can resume at the price we all want.
1 · Reply
Amb8675309
Amb8675309 Jul. 29 at 12:46 AM
$ITRM don’t confuse a cash runway issue with how the drug will do in the real world. After 9 years, an FDA approval, 14 year patent, of course the board & Fishman are going to politely decline any lowballs & go test this drug IRL- see how it does capturing market share. The details of the launch are coming. I can confirm the speciality pharmacy is not Eversana- may not even be Amazon. Either way, if you think this drug will prescribed(as I do, and as doctors do), it comes down to insurers. Will insurers stop asking women with co morbidities, who have already had ESBL producing e. Coli UTIs in past, to keep taking a generic every time they get a uUTI? The thinking is the insurer will see that, for this group, it’s ultimately cheaper to just prescribe Orlynvah from the get go for these women. That’s how Fishman is saying this drug can be a success getting even just 1% of the resistant cases. The isn’t a failure- it hasn’t even been marketed yet. Corey just needs $ for a full launch.
2 · Reply
zombieb
zombieb Jul. 29 at 12:33 AM
1 · Reply
Keepitmoving
Keepitmoving Jul. 29 at 12:24 AM
$ITRM Sounds like Iterum and Eversana are gearing up for the most pathetic launch ever. Targeted launch with limited distribution from a specialty pharmacy. Are you kidding me?! How pathetic. Please pump this over the next few weeks so I can leave.
2 · Reply
NYC4LYFE
NYC4LYFE Jul. 29 at 12:08 AM
$ITRM Random observation, according to that countdown clock which seems quite amateur, the date to register is August 19th at 4PM but the countdown to the event is before the registration by date. Maybe I’m wrong. Correct me if I am.
3 · Reply
gandolf63
gandolf63 Jul. 28 at 11:32 PM
$ITRM ai says A **virtual launch** for a newly FDA-approved drug is a digital-first strategy to introduce the product to healthcare professionals, investors, patients, and other stakeholders—without traditional in-person events. It’s become especially popular post-pandemic and can be incredibly effective when done right. 💡 **Here's what it typically includes:** - **Online Press Events:** Livestreamed or pre-recorded sessions featuring executives, researchers, and clinicians discussing the drug’s science, usage, and benefits. - **Webinars & Medical Education:** Virtual roundtables or CME-accredited presentations targeting healthcare providers. - **Digital Marketing Campaigns:** Use of email, social media, online ads, and medical platforms to generate buzz and inform audiences. - **Interactive Platforms:** Microsites or portals where users can explore drug data, watch explainer videos, or even schedule rep meetings. - **Patient Engagement Tools:**
0 · Reply
ASKING7
ASKING7 Jul. 28 at 11:10 PM
$ITRM the mind Game continues.
0 · Reply
Keepitmoving
Keepitmoving Jul. 28 at 10:51 PM
$ITRM I think she meant we will hear “dilution” plan next week. So many pumpers on this board. As a shareholder, it’s sickening.
0 · Reply
Keepitmoving
Keepitmoving Jul. 28 at 10:50 PM
$ITRM Pumping lunatic identified below 👇. He is NOT going to be cautious because he hasn’t even exhausted the current ATM. Also, YellowPumper, don’t you think it’s odd that Fatman refuses to say a peep about anything related to this launch?! You must be thoroughly impressed with his successes, right?!
1 · Reply
yellowjacker
yellowjacker Jul. 28 at 10:30 PM
$ITRM If I understand it right anyone will be able to log on the meeting. It's not by invitation only. I would think you would want any along with shareholders.
1 · Reply
iambaron
iambaron Jul. 28 at 10:16 PM
$ITRM hmm while Coyne is speaking, they may be using Eversana as a front for the event. This would allow them to not announce this material event and avoid a possible 8K. Now why would they want to avoid the public’s eye and try to be acting more behind the scenes. This would mean this is an invite only event. Now who would they be inviting to a virtual launch meeting showing their readiness and ability to bring Orynlvah to market… definitely not potential acquirers.
1 · Reply
yellowjacker
yellowjacker Jul. 28 at 10:01 PM
$ITRM Fishman has a cash run until the second quarter of 2026. Yes, he is going be conservative with the money. With a launch coming out in August it will give him 3 quarters of sales. Not knowing what the definitive 14A will hold, which may come out Friday, it would be prudent not to over react to a daily price swing that was up 3 cents and down 3 cents today. With my last buy at .81 if we hit .75 in the next couple days I will buy again. Let me close by saying Fishman and the board have been exercising their options over the past weeks who know alot more behind the scenes than we do. I will also add the group has more experience on their pinky finger when it comes to FDA approved drugs and buyouts than everyone on this board.
2 · Reply
gandolf63
gandolf63 Jul. 28 at 9:55 PM
$ITRM Can't figure out why they have not formally announced the virtual launch
1 · Reply